further demonstrated that dual engineering of NK cells with an EGFR vIII-targeted CAR and the CXC chemokine receptor 4 (CXCR4) augmented tumor infiltration capacity, thereby improving therapeutic outcomes in solid tumor models (66). This evidence concerns the gene EGFR and neoplasm.